Chris Bryant

Chris Bryant

Labour — Rhondda and Ogmore

Speaking in the House of Commons on 3 February 2025

Debate

AstraZeneca

Contribution

The thing is that spending taxpayers’ money has to be proven to be good value for money. That is why, whenever we are making an investment such as this, we have to make sure it delivers more return on investment than £1 for £1. When AstraZeneca made the decision to cut the R&D part of its budget from £150 million to £90 million, it made sense for the UK Government to look again at the amount of money we could legitimately put in on behalf of the taxpayer. If the hon. Lady had been in my place, I think she would have made exactly the same decision.

More from Chris Bryant

Other recent Hansard contributions by the same speaker.

About Hansard

Hansard is the official verbatim record of proceedings in the UK Parliament. Every word spoken in the Commons and Lords is recorded and published — this page is a single contribution from that record.

For Chris Bryant's full parliamentary record including voting history, expenses and all other contributions, see the Chris Bryant report card.